Moving forward with Takeda's live chimeric tetravalent dengue vaccine

Affiliations

¹ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore; Institute of Public Health, University of Heidelberg, Heidelberg, Germany; Department of Disease Control, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: awilder-smith@ntu.edu.sg.

Comment

Annelies Wilder-Smith. Lancet Infect Dis. 2017 Jun.

. 2017 Jun;17(6):566-568.

doi: 10.1016/S1473-3099(17)30165-2. Epub 2017 Mar 30.

¹ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore; Institute of Public Health, University of Heidelberg, Heidelberg, Germany; Department of Disease Control, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: awilder-smith@ntu.edu.sg.

No abstract available

Comment on

Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X, Tricou V, Yu D, Rivera L, Tuboi S, Garbes P, Borkowski A, Wallace D. Sáez-Llorens X, et al. Lancet Infect Dis. 2017 Jun;17(6):615-625. doi: 10.1016/S1473-3099(17)30166-4. Epub 2017 Mar 30. Lancet Infect Dis. 2017. PMID: 28365225 Clinical Trial.